$QNTA The registration enables Escozine® to be prescribed as a natural bioactive alternative medicine to be used in cancer treatments as well as a treatment for the SARS-CoV-2 (COVID-19) virus, after Medolife performed a safety and efficacy study on COVID-19. This registration in the DR through in-place trade agreements opens the door for distribution and sales in most of Latin America.

https://finance.yahoo.com/news/medolife-rx-an...00114.html